No tone at all, I was just referring to your post as it is confusing.
Gene Therapy and mRNA is certainly not interchangeable as far as FDA is concerned...but i see what you are getting at.
"Gene Therapy" in reference to Sarepta's program = using AVV/LVV vectors to introduce copy of damaged gene. Unfortunately the AVV vector causes a massive immune response in DMD boys that adds to the inflammation / fibrotic state.
So even though Sarepta was successful at increasing Dystrophin with corrective gene, there were no functional benefits / stopping disease progression....because of cycle of inflammation.
That's why ANP has said previously that ATL1102 "could" be a foundational drug that allows other drugs to work better / more efficacy.
Although recent data suggests ATL1102 may well be a 'standalone' treatment in it's own right.
...
ANP Price at posting:
21.0¢ Sentiment: Buy Disclosure: Held
(20min delay)